DeutschNewstral
Article
timesofisrael.com on 2019-01-08 14:07
Troubled Teva’s CEO sees prices in generic drug market stabilizing
Related news
- MMylan sees opportunity in rival Teva’s weaknessmarketwatch.com
- Teva’s shares surge as first quarter results beat expectationstimesofisrael.com
EU diplomat encourages stabilizing troubled Myanmar stateThe Fresno Bee
Teva’s Generic EpiPen U.S. Launch Still Stalled Five Months After ApprovalHaaretz
Germany sees Iran as key to stabilizing Middle EastThe Jerusalem Post (JPost.com)- HTeva’s Negev Plant Included in “Optimization” Processhamodia.com
Gasoline prices are inching down. Are other prices stabilizing in California?sacbee.com
Officials describe ‘cartel’ driving up generic drug pricesThe Press Democrat- Teva sees 25% of EpiPen auto-injector market by end 2019timesofisrael.com
- BTeva’s working with Evercore to review debt optionsbloomberg.com
Teva’s Indictment Came After Talks Faltered with Justice Departmentwsj.com- MTeva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debtmarketwatch.com
- BTeva’s Stock Slides After U.S. Sues Over Copay Kickback Claimsbarrons.com
- FInvestors question green tint of Teva’s $5bn sustainability bondft.com
- MTeva’s 100 Job Boostmunster-express.ie
- MTeva’s generic EpiPen approved in the U.S., with perfect timingmarketwatch.com
- HTeva Revenue Loss Amid Generic Competitionhamodia.com